AKT1 and melanoma: Despite evidence that perifosine treatment of melanoma cells reduces expression of p-Akt (Liu and Xing, 2012), a phase II trial in metastatic cutaneous melanoma patients failed to demonstrate efficacy [NCT00053781 (Ernst et al., 2005)].